Massachusetts Financial Services Co. MA Has $28.55 Million Stock Holdings in Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY)

Massachusetts Financial Services Co. MA boosted its position in Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY - Free Report) by 25.6% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 829,620 shares of the company's stock after acquiring an additional 169,229 shares during the quarter. Massachusetts Financial Services Co. MA owned 1.45% of Harmony Biosciences worth $28,547,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors have also recently added to or reduced their stakes in the company. Trexquant Investment LP purchased a new position in shares of Harmony Biosciences in the 4th quarter worth about $6,042,000. Geode Capital Management LLC raised its holdings in Harmony Biosciences by 22.8% in the fourth quarter. Geode Capital Management LLC now owns 902,934 shares of the company's stock valued at $31,077,000 after buying an additional 167,516 shares during the period. StoneX Group Inc. lifted its position in Harmony Biosciences by 10.0% during the fourth quarter. StoneX Group Inc. now owns 20,779 shares of the company's stock valued at $715,000 after buying an additional 1,897 shares in the last quarter. Franklin Resources Inc. lifted its position in Harmony Biosciences by 7.0% during the fourth quarter. Franklin Resources Inc. now owns 31,869 shares of the company's stock valued at $1,097,000 after buying an additional 2,096 shares in the last quarter. Finally, O Shaughnessy Asset Management LLC grew its stake in Harmony Biosciences by 2.1% during the fourth quarter. O Shaughnessy Asset Management LLC now owns 20,450 shares of the company's stock worth $704,000 after buying an additional 420 shares during the period. Hedge funds and other institutional investors own 86.23% of the company's stock.

Analysts Set New Price Targets

HRMY has been the topic of several recent research reports. Needham & Company LLC restated a "buy" rating and set a $50.00 target price on shares of Harmony Biosciences in a report on Tuesday. HC Wainwright reissued a "buy" rating and issued a $70.00 price objective on shares of Harmony Biosciences in a research report on Tuesday. Mizuho upped their target price on Harmony Biosciences from $42.00 to $44.00 and gave the stock an "outperform" rating in a research report on Tuesday, March 18th. Finally, Deutsche Bank Aktiengesellschaft began coverage on Harmony Biosciences in a report on Tuesday, February 11th. They set a "buy" rating and a $55.00 target price on the stock. Nine investment analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the stock has a consensus rating of "Buy" and an average price target of $53.33.

Harmony Biosciences Price Performance

Shares of NASDAQ:HRMY traded up $0.18 on Friday, reaching $29.17. 827,269 shares of the company traded hands, compared to its average volume of 568,427. The stock has a market capitalization of $1.67 billion, a PE ratio of 13.82, a P/E/G ratio of 0.47 and a beta of 0.80. The company has a debt-to-equity ratio of 0.28, a current ratio of 3.24 and a quick ratio of 3.20. The company's 50 day moving average is $33.89 and its 200-day moving average is $34.80. Harmony Biosciences Holdings, Inc. has a fifty-two week low of $26.47 and a fifty-two week high of $41.61.

Harmony Biosciences (NASDAQ:HRMY - Get Free Report) last issued its earnings results on Tuesday, February 25th. The company reported $0.85 EPS for the quarter, topping the consensus estimate of $0.74 by $0.11. The business had revenue of $201.30 million during the quarter, compared to analysts' expectations of $201.25 million. Harmony Biosciences had a return on equity of 23.16% and a net margin of 17.98%. Harmony Biosciences's revenue was up 19.5% compared to the same quarter last year. During the same quarter last year, the firm posted $0.45 earnings per share. As a group, analysts anticipate that Harmony Biosciences Holdings, Inc. will post 2.43 earnings per share for the current fiscal year.

Insider Activity at Harmony Biosciences

In other Harmony Biosciences news, insider Jeffrey Dierks sold 1,123 shares of the company's stock in a transaction dated Tuesday, January 21st. The shares were sold at an average price of $40.00, for a total transaction of $44,920.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CFO Sandip Kapadia sold 25,000 shares of the firm's stock in a transaction that occurred on Tuesday, January 21st. The shares were sold at an average price of $40.18, for a total value of $1,004,500.00. The disclosure for this sale can be found here. In the last 90 days, insiders sold 72,452 shares of company stock valued at $2,831,679. Insiders own 30.80% of the company's stock.

Harmony Biosciences Profile

Harmony Biosciences Holdings, Inc, a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare and other neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy.